Latest Administration News

Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.

DPM Metals has lodged a detailed technical report updating the Mineral Resource and Reserve estimates for its Chelopech mine in Bulgaria, underpinning its strategic growth plans.

Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.

Telix Pharmaceuticals has announced that Part 1 of its ProstACT Phase 3 trial for TLX591-Tx met its primary safety and dosimetry objectives, with no new safety concerns. The study’s success supports ongoing global enrolment in Part 2 and regulatory engagement in the US.

Suncorp Group Limited has updated the dividend reinvestment price for its fully franked ordinary dividend relating to the six months ending December 2025. The dividend of 17 cents per share will be paid on 31 March 2026, with flexible currency options for shareholders.

Mineral Commodities Limited has completed the sale of its Skaland Graphite Project in Norway for USD 8.75 million as part of its voluntary administration process. The transaction marks a significant step in the company’s restructuring efforts.

Cyclopharm Limited has responded to ASX queries clarifying the material significance of its Technegas® contract with the US National Institutes of Health, while confirming robust progress in expanding its US footprint.

Eureka Group Holdings has confirmed its ordinary dividend for the half-year ending December 2025, detailing payment terms including a Dividend Reinvestment Plan price and New Zealand Dollar exchange rate.

Ansell Limited has updated its FY26 interim dividend details, confirming a USD 0.266 per share payout and setting the Dividend Reinvestment Plan price at USD 22.24 per share. The dividend will be paid in US dollars with an Australian dollar equivalent of AUD 0.3768 per share.

Beetaloo Energy has responded to ASX concerns over a delayed disclosure of a director's change in interest, attributing it to an administrative oversight and pledging enhanced compliance measures.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

Diablo Resources has significantly increased its Star Range Silver-Antimony Project footprint in Utah by acquiring an additional 646.5 acres adjacent to the South Star Prospect, enhancing geological continuity and exploration potential.